Bausch Health in-licenses Eyenovia formulation

12 October 2020

Canada-headquartered Bausch Health (TSX: BHC) has acquired an exclusive license in the USA and Canada from Eyenovia (Nasdaq: EYEN) for the development and commercialization of an investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression, also known as near-sightedness, in children aged three-12 years.

This investigational formulation of atropine is delivered with Eyenovia's proprietary Optejet dispenser technology, and news of the deal saw the US company’s shares gain nearly 9% to $3.69 pre-market today.

Myopia is among the most common ocular disorders worldwide and is a leading cause of visual impairment in children. In the USA, myopia is estimated to affect approximately 25 million children, with up to 3 million considered to be at risk for high myopia.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK